Condition (MeSH)
Hemangioma, Capillary
ClinicalTrials.gov lists 65 trials for Hemangioma, Capillary or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
49 of the 65 trials are tagged with Hemangioma, Capillary itself; the rest are tagged with a narrower condition beneath it.
When did Hemangioma, Capillary trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 3 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 40 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangioma, Capillary trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 14 |
| Phase 2/3 | 4 |
| Phase 3 | 3 |
| Phase 4 | 4 |
| Not applicable | 16 |
| Observational | 19 |
How many Hemangioma, Capillary trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 11 |
| Active, not recruiting | 1 |
| Completed | 31 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangioma, Capillary trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 3 |
| Sklifosovsky Institute of Emergency Care | 3 |
| Pierre Fabre Dermatology | 2 |
| AFT Pharmaceuticals, Ltd. | 1 |
| Auson Pharmaceuticals Inc. | 1 |
Which drugs are being tested for Hemangioma, Capillary? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nadolol | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Propranolol PO | 12 |
| topical 0.5% Timolol | 2 |
| Control (placebo) group | 2 |
| Atenolol Pill | 2 |
| Sunitinib 4/2 | 2 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemangioma, Capillary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Bronchiolitis | 12 | 3 |
| Fatigue | 9 | 1 |
| Thrombocytopenia | 6 | 1 |
| Lymphopenia | 5 | 1 |
| Bronchitis | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hemangioma, Capillary? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. | JAMA pediatrics | 2022 | Yes |
| Hemangiol in infantile haemangioma: A paediatric post-marketing surveillance drug study. | British journal of clinical pharmacology | 2021 | Yes |
| Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. | JAMA otolaryngology-- head & neck surgery | 2021 | Yes |
| Systemic timolol exposure following topical application to infantile hemangiomas. | Journal of the American Academy of Dermatology | 2020 | Yes |
| Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation. | Plastic and reconstructive surgery | 2017 | Yes |
Showing 5 of 15 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.